Two proteins (CR1 with AD in basal ganglia, cortex and hippocampus; and GRN with AD in cerebellum, cortex and hippocampus) were found to have evidence for co-localization with disease risk from mRNA abundance in three brain regions, and a further six proteins (ACE, CD33, CTSH and SIRPA with AD in cerebellum and cortex; LRRC37A2 with AD in cortex and hippocampus; and PVR with MS in cerebellum and cortex) have support for co-localization with mRNA abundance in two brain regions. The gene discussed is CD33; the disease is myeloid sarcoma.